NASDAQ:CALA - Calithera Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.30 0.00 (0.00 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$5.30
Today's Range$5.05 - $5.35
52-Week Range$4.70 - $20.05
Volume973,925 shs
Average Volume357,718 shs
Market Capitalization$189.98 million
P/E Ratio-6.31
Dividend YieldN/A
Beta2.53
Calithera Biosciences logoCalithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CALA
CUSIPN/A
Phone650-870-1000

Debt

Debt-to-Equity RatioN/A
Current Ratio5.27
Quick Ratio5.27

Price-To-Earnings

Trailing P/E Ratio-6.31
Forward P/E Ratio-3.79
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.95 million
Price / Sales7.32
Cash FlowN/A
Price / CashN/A
Book Value$4.24 per share
Price / Book1.25

Profitability

EPS (Most Recent Fiscal Year)($0.84)
Net Income$-27,820,000.00
Net Margins-131.51%
Return on Equity-22.92%
Return on Assets-17.93%

Miscellaneous

Employees73
Outstanding Shares35,850,000

The Truth About Cryptocurrencies

Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences Inc (NASDAQ:CALA) issued its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.37) EPS for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.05. The biotechnology company earned $5.19 million during the quarter, compared to the consensus estimate of $7.28 million. Calithera Biosciences had a negative return on equity of 22.92% and a negative net margin of 131.51%. View Calithera Biosciences' Earnings History.

What price target have analysts set for CALA?

3 brokers have issued twelve-month target prices for Calithera Biosciences' stock. Their predictions range from $14.00 to $14.00. On average, they anticipate Calithera Biosciences' stock price to reach $14.00 in the next year. View Analyst Ratings for Calithera Biosciences.

Who are some of Calithera Biosciences' key competitors?

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the folowing people:
  • Dr. Susan M. Molineaux, Co-Founder, CEO, Pres, Principal Financial Officer & Director (Age 64)
  • Dr. Keith Orford M.D., Ph.D., Sr. VP of Clinical Devel. (Age 46)
  • Ms. Stephanie Wong, Sr. VP of Fin., Sec. & Principal Accounting Officer (Age 44)
  • Ms. Jennifer McNealey, VP of Investor Relations & Strategy
  • Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer

Has Calithera Biosciences been receiving favorable news coverage?

News stories about CALA stock have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Calithera Biosciences earned a media sentiment score of 0.01 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.76 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.01%), Federated Investors Inc. PA (3.97%), American Century Companies Inc. (2.22%), Millennium Management LLC (1.99%), Franklin Resources Inc. (1.79%) and Dimensional Fund Advisors LP (1.32%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Institutional Ownership Trends for Calithera Biosciences.

Which major investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Franklin Resources Inc. and Barclays PLC. Company insiders that have sold Calithera Biosciences company stock in the last year include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Insider Buying and Selling for Calithera Biosciences.

Which major investors are buying Calithera Biosciences stock?

CALA stock was purchased by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, BlackRock Inc., Dimensional Fund Advisors LP, American Century Companies Inc., GSA Capital Partners LLP, Candriam Luxembourg S.C.A., Alambic Investment Management L.P. and Dynamic Technology Lab Private Ltd. View Insider Buying and Selling for Calithera Biosciences.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $5.30.

How big of a company is Calithera Biosciences?

Calithera Biosciences has a market capitalization of $189.98 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]


MarketBeat Community Rating for Calithera Biosciences (CALA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  184 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  313
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.